‘英创’已研发了一系列新一代的抗体来抑制多种细胞内的抗原，从而用来治疗不同的肿瘤类型。
* Additional Phase 2 HSA approved trial ongoing in Singapore NCC
** Additional Phase 2 HSA approved trial ongoing in Singapore NCC
里程碑
2008
new concept on Cancer Immunotherapy
2017
Phase I clinical trial in Singapore
2019
Phase II clinical trial in Singapore
2020
Phase II clinical trial in USA
2021
Phase II clinical trial in CHINA
